Treating peripheral vascular disease. Migraine therapy Flashcards
Mechanism of the drugs that treat peripheral vascular disease
Vasodilation
Rheological effect - RBC modification
Platelet inhibition - aggregation inhibitors.
Peripheral vascular diseases listed on the elearning
- (3Ns, B3)
Naftidrofuryl
Nicergoline
Niacin (B3)
Cinnarizine and Flunarizine
Vinpocetine
Pentoxifylline
Bencyclane
Naftidrofuryl
increases peripheral circulation
SEs: Arrythmia, hypotension, angina
Nicergoline
ErGOt derivative, but nicer :D
alpha1 inhibition
platelet inhibition
increases Dopamine in the brain.
Used for peripheral vasc. diseases and sometimes in dementia or cerebral casvular disease.
Cinnarizine and Flunarizine
CCBs, inhibit: Ca channels, Platelet aggregation RBC rigidity Histamine receptors
SEs: Depression, sedation
Pentoxifylline
Methylxanthine derivative, nonspecific PDE inhibitor.
inhibits platelet aggregation and decreases RBC blood viscocity.
for Atherosclerotic and Diabetic PVD.
claudication
sickle cell anemia
Orally admined, SEs: GI upset, tachycardia, angina flushing
Niacin
Decreases VLDL and LDL levels, (decreasing triglycerides)
Mild increase in HDL, most effective HDL increaser.
Rx:
Atherosclrotic PVD
Vasospastic PVD
SE:
LIVER damage, possibly severe. Liver monitoring is manditory.
flushing - caused by prostaglandins, limited by NSAID pretreatment
Hypotension
Tachydcardia
Hyperglycemia
Hyperuricemia and Gout - Allopurinol.
Ones not listed on the elearning
Amlodipine and the dihydropyridine CCBs are 1st line for Raynauds
Cilostazol and Dipyridamole - PDE inhibitors, treat symptoms of PAD. inhibit platelet aggregation and cause arteriolar vasodilation.
Clopidogrel, Prasugrel, Ticagrelor, and Ticlodipine ADP receptor P2Y12 inhibitors.
-prophylaxis to decrease the associated MI risk.
Statins are indicated in PAD.
-Decrease atherosclerosis and MI risk.